DK1512014T3 - Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation - Google Patents

Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation

Info

Publication number
DK1512014T3
DK1512014T3 DK03738030T DK03738030T DK1512014T3 DK 1512014 T3 DK1512014 T3 DK 1512014T3 DK 03738030 T DK03738030 T DK 03738030T DK 03738030 T DK03738030 T DK 03738030T DK 1512014 T3 DK1512014 T3 DK 1512014T3
Authority
DK
Denmark
Prior art keywords
transplantation
allo
antigens
alloantigens
identifying
Prior art date
Application number
DK03738030T
Other languages
English (en)
Inventor
Wolfgang Strittmatter
Heidrun Moll
Burkhard Scharm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1512014T3 publication Critical patent/DK1512014T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
DK03738030T 2002-06-13 2003-06-13 Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation DK1512014T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013423 2002-06-13
PCT/EP2003/006251 WO2003106692A2 (en) 2002-06-13 2003-06-13 Methods for the identification of all-antigens and their use for cancer therapy and transplantation

Publications (1)

Publication Number Publication Date
DK1512014T3 true DK1512014T3 (da) 2009-10-05

Family

ID=29724392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03738030T DK1512014T3 (da) 2002-06-13 2003-06-13 Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation

Country Status (11)

Country Link
US (1) US20050244421A1 (da)
EP (2) EP2110669B1 (da)
JP (2) JP2005529187A (da)
AT (2) ATE438857T1 (da)
AU (1) AU2003245942B2 (da)
CA (1) CA2489296A1 (da)
DE (1) DE60328685D1 (da)
DK (1) DK1512014T3 (da)
ES (2) ES2329461T3 (da)
PT (1) PT1512014E (da)
WO (1) WO2003106692A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489296A1 (en) * 2002-06-13 2003-12-24 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for the identification of allo-antigens and their use for cancer therapy and transplantation
JP2005102599A (ja) * 2003-09-30 2005-04-21 Shimadzu Corp Ｈｌａタイピング法
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
KR101314899B1 (ko) * 2005-03-22 2013-10-04 로도세이야구가부시기가이샤 콜라겐 또는 히알루론산 생성을 증가시키는 펩티드
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
PT2200622E (pt) 2007-09-19 2012-11-06 Pluristem Ltd Células aderentes provenientes de tecido adiposo ou placentário e respetiva utilização terapêutica
WO2009037297A2 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
US20120165211A1 (en) * 2007-09-20 2012-06-28 Bracco Imaging S.P.A. Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques
KR20110014595A (ko) 2008-04-18 2011-02-11 유니버시티 오브 테네시 리서치 파운데이션 단일 염기 다형성（ｓｎｐ） 및 면역 관용 유도에 대한 저항과의 관련
EP2641606A1 (en) * 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2010026735A1 (ja) * 2008-09-05 2010-03-11 国立大学法人名古屋大学 アミロイドβ凝集促進ペプチド及びその用途
KR102017898B1 (ko) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
EP2612149B1 (en) * 2010-06-21 2017-08-09 Innatoss Laboratories B.V. Compositions and methods for diagnosing and monitoring disease and treatment via antigen-specific molecules
CN103608033B (zh) 2011-05-24 2016-06-15 生物技术公司 用于癌症的个体化疫苗
RU2508552C2 (ru) * 2011-06-17 2014-02-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Минздравсоцразвития России" Способ прогнозирования развития злокачественных солидных опухолей у детей и подростков
EP3486315A1 (en) * 2012-03-06 2019-05-22 Cellect Biotherapeutics Ltd. Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3083684A1 (en) 2013-12-06 2016-10-26 NovImmune SA Anti-tlr4 antibodies and methods of use thereof
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
EP3998481A1 (en) 2014-09-10 2022-05-18 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
BR112019005633A8 (pt) * 2016-09-23 2023-04-11 Hutchinson Fred Cancer Res Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US20220309810A1 (en) * 2021-03-26 2022-09-29 Howard University Method for the detection, segmentation and morphological mapping on neural cell images of the whole brain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
DE69635856T2 (de) * 1995-07-25 2006-11-16 Rijksuniversiteit Te Leiden Antigenische ha-2 peptide
CA2224894A1 (en) 1995-07-27 1997-02-13 Els A.J.M. Goulmy The h-y antigen
JP2002510978A (ja) 1997-07-23 2002-04-09 レイクスウニヴェルシテイト レイデン 副組織適合性抗原ｈａ―１のタイピング法
EP1020519A1 (en) * 1999-01-15 2000-07-19 Introgene B.V. Minor histocompatibility antigens and their use in the diagnosis and treatment of tumors
EP1067141A1 (en) 1999-06-11 2001-01-10 Rijksuniversiteit te Leiden A male-specific protein homologue involved in histocompatibility
US20020018776A1 (en) * 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
CA2489296A1 (en) * 2002-06-13 2003-12-24 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for the identification of allo-antigens and their use for cancer therapy and transplantation

Also Published As

Publication number Publication date
ATE438857T1 (de) 2009-08-15
EP2110669A1 (en) 2009-10-21
EP2110669B1 (en) 2011-08-03
EP1512014B1 (en) 2009-08-05
JP2010252806A (ja) 2010-11-11
DE60328685D1 (de) 2009-09-17
US20050244421A1 (en) 2005-11-03
ES2329461T3 (es) 2009-11-26
AU2003245942A1 (en) 2003-12-31
PT1512014E (pt) 2009-11-10
CA2489296A1 (en) 2003-12-24
EP1512014A2 (en) 2005-03-09
AU2003245942B2 (en) 2008-07-24
WO2003106692A2 (en) 2003-12-24
ES2370688T3 (es) 2011-12-21
JP2005529187A (ja) 2005-09-29
ATE519115T1 (de) 2011-08-15
WO2003106692A3 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
DK1512014T3 (da) Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation
ES2836273T3 (es) Método para el tratamiento del cáncer
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
EA200971124A1 (ru) Множественный анализ образцов крови
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
DK1187591T3 (da) IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
ATE474851T1 (de) Verfahren zur identifizierung antigener peptide
MX2021015033A (es) Clasificacion con contraseleccion utilizando peptidos de secuencias similares.
ATE454159T1 (de) Von survivin abgeleitete peptide und deren verwendung
CA2735138C (en) Screening methods for transfusion related acute lung injury (trali)
WO2020014097A8 (en) Reagents and methods for treating cancer and autoimmune disease
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
ATE316577T1 (de) Das goodpasture-antigen bindende protein
EA202091713A1 (ru) Биологический синтез аминокислотных цепей для получения пептидов и белков
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
ZA200500214B (en) Method for mapping and eliminating T-cell epitopes.
HUP0400661A2 (hu) Specifikus tumorantigének azonosítása cDNS-könyvtárak szérumokkal történő szelekciójával, és az antigének alkalmazása daganatok kezelésében
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
WO2019118906A3 (en) Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
WO2006089002A3 (en) Method for high throughput screening for antibodies and proteins inducing apoptosis
WO2020099674A3 (en) Novel c-met and tmx2 antibodies
MX2023013568A (es) Proteina sintetica para inducir inmunotolerancia.
EA201990736A1 (ru) Белковые биомаркеры заболеваний, ассоциированных с контактной системой активации